Teva Pharmaceutical Industries Limited (TEVA) has been under a strong bear grip, hence the stock is down -0.34% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.5% in the past 1 week. The stock has risen by 3.05% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.36% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 0.3% and the 50-Day Moving Average is 1.7%.The 200 Day SMA reached 6.64% Teva Pharmaceutical Industries Limited is up 0.12% in the last 3-month period. Year-to-Date the stock performance stands at -19.66%.
Teva Pharmaceutical Industries Limited (TEVA) has been rated by 16 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $100 and the lowest price target forecast is $57. The average forecast of all the analysts is $71.68 and the expected standard deviation is $10.67.
For the current week, the company shares have a recommendation consensus of Buy. Teva Pharmaceutical Industries Limited (NYSE:TEVA): stock was range-bound between the intraday low of $51.45 and the intraday high of $52.01 after having opened at $51.89 on Fridays session. The stock finally closed in the red at $51.89, a loss of -0.31%. The stock remained in the red for the whole trading day. The total traded volume was 4,650,728 shares. The stock failed to cross $52.01 in Fridays trading. The stocks closing price on Thursday was $51.74.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.